Twin Beta-Al Tablets 80/5/10 mg (Telmisartan, Amlodipine, Rosuvastatin)
Telmisartan · Amlodipine Besylate +1 more
Prescription medication · Combination
Daewoong Bio Co., Ltd.
MFDS item code 201803890 · Approved 2018.10.02
This product's status changed to Approval withdrawn on 2023.04.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk
This medication is used for patients with essential hypertension who cannot adequately control their blood pressure with telmisartan and amlodipine combination therapy, as well as those who need to be administered rosuvastatin simultaneously. The telmisartan/amlodipine combination helps to manage hypertension that is insufficiently controlled by monotherapy. Rosuvastatin is used as an adjunct in patients with hypercholesterolemia and mixed dyslipidemia that are not improved by diet and exercise, and it is also effective in certain patients with familial hypercholesterolemia. Additionally, it is helpful in treating patients with homozygous familial hypercholesterolemia or dysbetalipoproteinemia, and lowers total cholesterol and LDL cholesterol to delay the progression of atherosclerosis. In middle-aged patients at high risk for cardiovascular disease, a reduction in the risk of stroke, myocardial infarction, and arterial revascularization can be expected. Therefore, this medication is used to improve cardiovascular health through the management of blood pressure and blood lipids.
This medicine should be taken once daily as 1 tablet with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin as separate products, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as follows, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this medicine 40/10 milligrams. ◦ Patients with renal impairment: No dose adjustment is needed for patients with mild or moderate renal impairment. For patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Special caution is required when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the rosuvastatin 40 milligrams dose is contraindicated in some of these patients. In a drug interaction study of the active ingredients in this medicine, telmisartan/amlodipine 80/10mg and rosuvastatin 20mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased by approximately 2.4-fold and AUC by approximately 1.3-fold. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.
This medication can cause serious harm to the fetus and newborn during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be administered to patients with hypersensitivity to any component of the medication, certain hereditary angioedema conditions, severe liver impairment or kidney impairment, or severe aortic stenosis. Caution is necessary when prescribing to elderly patients, those with low blood pressure, those with compromised liver function, or those at risk for hyperkalemia, and regular monitoring may be needed. If symptoms such as muscle pain or weakness occur, it is important to consult a healthcare professional immediately and regularly check muscle-related test values. This medication may affect liver and kidney function; therefore, regular liver and kidney function tests should be conducted. As this medication can interact with other drugs, it is essential to inform your healthcare provider of any other medications you are currently taking. Women who could become pregnant should use appropriate contraception, and it is safe not to take this medication while breastfeeding. It is not recommended for children or adolescents under the age of 18. In case of overdose, symptoms such as low blood pressure, dizziness, and heart rhythm abnormalities may occur, requiring immediate medical attention. This medication should be kept out of reach of children and should not be transferred to another container.
This medication is sensitive to light and should be stored in a container protected from light. Additionally, it is important to store it at a cool room temperature, specifically between 1 degree and 30 degrees Celsius to maintain the drug's effectiveness.
Bright pink oval film-coated tablets
30 tablets (10 tablets x 3)/PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Telmisartan · Amlodipine Besylate +1 more
Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Telmisartan 80mg · Amlodipine Besylate 13.87mg +1 more
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Il Dong Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Telmisartan 80mg · Amlodipine Besylate 13.87mg +1 more
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.